Probenecid

Probenecid. It is a medication primarily used to treat gout and hyperuricemia by increasing the excretion of uric acid in the urine. Developed in the mid-20th century, it functions as a uricosuric agent and is also employed to prolong the activity of certain antibiotics like penicillin by reducing their renal clearance. Its use has declined with the advent of newer agents such as allopurinol and febuxostat, but it remains a recognized option in specific clinical scenarios.

Medical uses

The primary medical use is in the management of chronic gout and tophaceous gout, where it helps lower serum uric acid levels to prevent acute gouty arthritis and the formation of tophi. It is also indicated as an adjunct to antibiotic therapy, particularly with penicillin G and cephalosporins like cefazolin, to elevate and prolong their plasma concentrations by competitively inhibiting their secretion in the renal tubules. This application is valuable in treating serious infections such as neurosyphilis or endocarditis caused by susceptible organisms. Its use is generally reserved for patients who are intolerant or have contraindications to first-line xanthine oxidase inhibitors.

Adverse effects

Common adverse effects involve the gastrointestinal tract, including nausea, vomiting, and anorexia. A significant risk is the formation of urate nephrolithiasis or uric acid stones, especially during initial therapy, which necessitates adequate hydration and often alkalinization of the urine. Hypersensitivity reactions such as skin rash, pruritus, and rarely, anaphylaxis have been reported. Other potential effects include headache, dizziness, and hepatic necrosis, with the latter being a rare but serious complication noted in some patients.

Pharmacology

Probenecid acts by potently inhibiting the organic anion transporter (OAT) systems, specifically OAT1 and OAT3, in the proximal convoluted tubule of the nephron. This inhibition blocks the tubular reabsorption of uric acid, thereby increasing its urinary excretion. Concurrently, it competitively inhibits the secretion of other organic acids, including many beta-lactam antibiotics, via the same transport pathway, which reduces their renal clearance. It is well-absorbed from the gastrointestinal tract, extensively bound to plasma proteins, and metabolized primarily by glucuronidation and oxidation in the liver, with excretion via the kidneys.

History

Probenecid was developed in the 1950s by scientists at Sharp & Dohme (later part of Merck & Co.) during research aimed at prolonging the action of penicillin. Its uricosuric properties were discovered serendipitously, leading to its approval by the Food and Drug Administration for the treatment of gout. For decades, it was a mainstay therapy until the introduction of allopurinol in the 1960s, which offered a different mechanism of action. Its role in antibiotic potentiation has been recognized in guidelines from organizations like the Infectious Diseases Society of America for specific infections.

Society and culture

Probenecid is available as a generic medication and is marketed under brand names including Probalan. It is listed on the World Health Organization's List of Essential Medicines. In popular culture, it has been referenced in contexts related to doping in sport, as it can mask the presence of other substances in urinalysis by inhibiting their excretion, leading to its inclusion on the World Anti-Doping Agency prohibited list. Its development story is often cited in pharmacology textbooks as a classic example of a drug with a discovered secondary therapeutic application. Category:Drugs